中国P站

The evolving landscape of oncology has increasingly embraced the paradigm of precision prevention—an approach that aims to reduce cancer risk by tailoring interventions based on individual genetic, environmental, and lifestyle profiles. Unlike traditional population-wide prevention models, precision prevention in oncology recognizes that each person’s risk is influenced by a unique combination of inherited genetic variants, modifiable behaviors, and environmental exposures [1-5]. Advances in genomic technologies, bioinformatics, and behavioral sciences have made it possible to identify high-risk individuals and intervene early with personalized strategies. These may include enhanced surveillance, prophylactic therapies, lifestyle modifications, or targeted education. As cancer incidence continues to rise globally, particularly in aging populations, the integration of precision prevention into clinical and public health systems offers a strategic and cost-effective pathway to reduce both cancer burden and health disparities. This approach not only improves outcomes through early intervention but also empowers individuals with actionable knowledge about their health risks [6-10].

Discussion

Genetic predisposition plays a central role in the development of certain cancers, such as those related to BRCA1/2 mutations in breast and ovarian cancer or MLH1 and MSH2 mutations in Lynch syndrome. Precision prevention uses genetic testing and family history analysis to identify individuals who may benefit from tailored risk-reduction strategies, such as earlier or more frequent screening, chemoprevention, or prophylactic surgery. For example, carriers of BRCA mutations may consider risk-reducing mastectomy or oophorectomy, while individuals with Lynch syndrome are monitored more aggressively for colorectal and endometrial cancers. Integrating genetic counseling into primary care and oncology practices ensures that individuals receive appropriate interpretation of test results and guidance on available preventive options.

Beyond genetics, lifestyle factors such as diet, physical activity, alcohol consumption, tobacco use, and body weight significantly influence cancer risk. Precision prevention considers these modifiable elements in combination with genetic risk to develop comprehensive risk profiles. Tools like polygenic risk scores (PRS) and predictive modeling allow clinicians to stratify individuals into risk categories and provide tailored recommendations. For example, a patient with a moderate genetic risk of colon cancer but a sedentary lifestyle and poor diet may be advised to adopt specific dietary and exercise regimens alongside routine colonoscopy screening.

Epigenetics, the study of how gene expression is influenced by environmental and behavioral factors without altering the DNA sequence, also supports the rationale behind precision prevention. Research shows that certain exposures—such as chronic stress, poor diet, or pollution—can alter gene function through epigenetic modifications, thereby increasing cancer susceptibility. Understanding these mechanisms enhances our ability to design preventive strategies that are not only genetically informed but also environmentally responsive.

Digital health technologies, such as mobile apps and wearable devices, further enable the implementation of precision prevention by tracking health behaviors, promoting adherence to preventive recommendations, and facilitating real-time communication with healthcare providers. Machine learning algorithms can analyze data from electronic health records, genomics, and patient-reported outcomes to continuously refine risk assessments and optimize preventive interventions.

However, precision prevention faces challenges, particularly in terms of accessibility, cost, and ethical considerations. Genetic testing and advanced screening technologies are not yet equitably distributed, and underserved populations may lack access to personalized care. There is also a risk of over-medicalization or psychological distress resulting from the identification of elevated genetic risk without immediate clinical action. Therefore, precision prevention must be accompanied by robust ethical frameworks, health education, and supportive counseling services.

In public health, integrating precision prevention requires coordination between clinical care, research institutions, policymakers, and communities. Population screening programs may be refined using genomic data to focus resources on those most likely to benefit, thereby improving efficiency and outcomes. Educational campaigns should also emphasize that while genetics can inform risk, lifestyle choices remain a powerful tool in cancer prevention, reinforcing the importance of healthy living across all risk groups.

Conclusion

Precision prevention in oncology represents a transformative shift in how we approach cancer risk reduction. By aligning preventive strategies with an individual’s genetic makeup and lifestyle factors, this model offers a targeted, efficient, and empowering pathway to reduce cancer incidence. Advances in genomic testing, data analytics, and personalized health technologies are making it increasingly feasible to identify high-risk individuals and intervene before disease onset. However, for precision prevention to achieve its full potential, challenges such as equitable access, ethical concerns, and integration into routine care must be addressed. Collaboration between clinicians, researchers, public health professionals, and policymakers is essential to build systems that support personalized, preventive oncology on a broad scale. Ultimately, precision prevention embodies the principle of proactive, patient-centered care—helping people understand, manage, and mitigate their personal cancer risk through informed choices and timely interventions.

References

1. Proc P, Szczepanska J, Skiba A, Zubowska M, Fendler W, et al.. Cancer Res Treat 48: 658-667.

,,

1. Voskuilen IGMVDP, Veerkamp JSJ, Raber-Durlacher JE, Bresters D, Wijk AJV, et al (2009). Support Care Cancer 17: 1169-1175.

,,

1. Ackerman JL, Acherman LA, Ackerman BA (1973). Am J Phys Anthropol 38: 681-694.

,,

1. Jafarzadeh H, Azarpazhooh A, Mayhall JT (2008). Int Endod J 41: 375-388.

,,

1. Kaste SC, Hopkins KP, Jones D, Crom D, Greenwald CA, et al. (1997). Leukemia 11: 792-796.

,,

1. Agha RA, Franchi T, Sohrabi C, Mathew G (2020). Int J Surg 84: 226-230.

,,

1. Eyman RK, Grossman HJ, Chaney RH, Call TL (1990). N Engl J Med 323: 584-589.

,,

1. Crimmins EM, Zhang Y, Saito Y (2016). Am J Public Health 106: 1287-1293.

,,

1. Nishimura S, Inada H, Sawa Y, Ishikawa H (2013). Eur J Cancer Care 22: 353-360.

,,

1. Hölttä P, Alaluusua S, Pihkala UMS, Wolf S, Nyström M, et al. (2002). Bone Marrow Transplant 29: 121-127.

,,